logo

For the Inventor, By the Inventor

Waltham, MA, United States of America

Regenacy Pharmaceuticals, LLC


USPTO Granted Patents = 16



Forward Citations = 24

Loading Chart...
Loading Chart...

10 inventors (with patents filed for the assignee):

goldMedal Ralph Mazitschek (12 out of 62 patents)

silverMedal John Henry Van Duzer (12 out of 54 patents)

bronzeMedal Matthew B Jarpe (4 out of 5 patents)

4.  Annemieke Kavelaars (2 out of 3 patents)

5.  Cobi J Heijnen (2 out of 3 patents)

6.  Karen Krukowski (2 out of 2 patents)

7.  Olga Golonzhka (2 out of 2 patents)

8.  Charles Blum (1 out of 1 patent)

9.  Ralph Mazitschek (0 patent)


16 patents:

1. 11858919 - HDAC1,2 inhibitors (2024-01-02),
2. 11702389 - Piperidine derivatives as HDAC1/2 inhibitors (2023-07-18),
3. 11542242 - Substituted piperazines as selective HDAC1,2 inhibitors (2023-01-03),
4. 11013740 - Histone deacetylase 6 selective inhibitors for the treatment of cisplatin-induced peripheral neuropathy (2021-05-25),
5. 10968180 - Piperidine derivatives as HDAC1/2 inhibitors (2021-04-06),
6. 10858323 - HDAC inhibitors for the treatment of diabetic peripheral neuropathy (2020-12-08),
7. 10774056 - Substituted piperazines as selective HDAC1,2 inhibitors (2020-09-15),
8. 10385031 - Substituted piperazines as selective HDAC1,2 inhibitors (2019-08-20),
9. 10358421 - Piperidine derivatives as HDAC1/2 inhibitors (2019-07-23),
10. 10272084 - Histone deacetylase 6 selective inhibitors for the treatment of cisplatin-induced peripheral neuropathy (2019-04-30),
11. 10239837 - Piperidine derivatives as HDAC1/2 inhibitors (2019-03-26),
12. 10125131 - Selective HDAC3 inhibitors (2018-11-13),
13. 10040769 - HDAC inhibitors for the treatment of diabetic peripheral neuropathy (2018-08-07),
14. 9957259 - Selective HDAC1 and HDAC2 inhibitors (2018-05-01),
15. 9790180 - Piperidine derivatives as HDAC1/2 inhibitors (2017-10-17),
Regenacy Pharmaceuticals, LLC is a biopharmaceutical company focused on the development of novel drug candidates for the treatment of neurodegenerative diseases. They aim to improve the lives of patients suffering from diseases such as multiple sclerosis (MS) and peripheral neuropathies. Regenacy Pharmaceuticals takes a unique approach by repurposing existing drugs and optimizing their efficacy in order to provide safe and effective treatment options for these challenging conditions.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

...
16 Patents

#75 in Waltham, MA

#1,160 in Massachusetts

#19,271 in US

#36,634 in the World

...
Waltham, MA, United States of America

Regenacy Pharmaceuticals, LLC

Forward Citations = 24

10 inventors:

goldMedal Ralph Mazitschek (12 out of 62 patents)

silverMedal John Henry Van Duzer (12 out of 54 patents)

bronzeMedal Matthew B Jarpe (4 out of 5 patents)

4.  Annemieke Kavelaars (2 out of 3 patents)

5.  Cobi J Heijnen (2 out of 3 patents)

Please report any incorrect information to support@idiyas.com
Loading…